Replies to post #125997 on Biotech Values

[north40000]

Werber never thought much of Yervoy while it was in development either--I cannot remember whether he has ever been + about anything.

[mcbio]

The analyst also noted that Benlysta may face competition in the next few years from other drugs in late-stage clinical development, and those potential treatments have the advantage of learning from Benlysta's trial-design shortcomings.

What exactly were Benlysta's trial-design shortcomings and has IMMU incorporated knowledge of such shortcomings into their Phase 3 trials for their lupus drug?

[drbio45]

It is only bullish for IMMU if IMMU meets its endpoints